Abstracts tagged "Therapy, alternative"

Abstract Number: PP05 • ACR Convergence 2023
Relief Redefined: A Patient’s Journey to Reducing the Impact of Her PsA Flare Ups
Caitlin West, Advocate, Coatesville, PA
Background/Purpose: I was diagnosed with Psoriatic Arthritis (PsA) ten years ago, at 25. I had been dealing with stiffness and chronic fatigue for most of…
Abstract Number: 0423 • ACR Convergence 2023
Detection of Citrullinated Proteins Recognized by a Novel Chimeric Antigen Receptor TregTherapy in Both Synovial Fluid and Serum from Patients with Rheumatoid Arthritis
Sara Charmsaz¹, Jeff Tracy¹, Elizabeth Whalen¹, John Bui¹, Anne-Renee van der Vuurst de Vries¹, Vivianne Malmström² and Michelle Blake¹, ¹Sonoma Biotherapeutics, Seattle, WA, ²Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Rheumatoid arthritis (RA) is one of the most common autoimmune diseases and despite many therapeutic options, an unmet medical need persists for novel therapies…
Abstract Number: 0436 • ACR Convergence 2023
Patients with Difficult-to-treat Rheumatoid Arthritis Have Higher Levels of Inflammation on Ultrasound
Ummugulsum Gazel¹, Seyyid Bilal Acikgoz², Catherine Ivory³, Amin Zahrai³, Ozun Bayindir Tsechelidis⁴, Ricardo Sabido-Sauri¹, Elliot Hepworth¹ and sibel aydin⁵, ¹University of Ottawa, Ottawa, ON, Canada, ²University of Ottawa, Rheumatology, Ottawa, ON, Canada, ³The Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁴Ottawa University, Ottawa, ON, Canada, ⁵University of Ottawa - Ottawa, Ottawa, ON, Canada
Background/Purpose: With increasing numbers of advanced therapies, rheumatologists frequently see Rheumatoid Arthritis (RA) patients who have failed ≥2 advanced therapies with different mechanisms of action.…
Abstract Number: 0585 • ACR Convergence 2023
The Impact of Impaired Vagus Nerve Activity and Transcutaneous Vagus Nerve Stimulation (tVNS) on Arterial Stiffness in Systemic Lupus Erythematosus (SLE)
Tobias Schmidt¹, Christina Brock², Jesper Fleischer³, Søren Jacobsen¹ and Amanda Hempel Zinglersen¹, ¹Copenhagen Research Center for Autoimmune Connective Tissue Diseases, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ²Department of Gastroenterology and Hepatology, Aalborg University Hospital and Clinical Institute, Aalborg, Denmark, ³Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic inflammatory autoimmune disease with an increased risk of atherosclerosis. The development of atherosclerosis in SLE cannot be…
Abstract Number: 0677 • ACR Convergence 2023
Analysis of Clinical Outcomes in Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treated with Mepolizumab over 2 Years for Remission Induction or Maintenance: A Single Center Experience in Japan
SOKO KAWASHIMA¹, Yoshinori Komagata¹, Mitsumasa Kishimoto² and Shinya Kaname¹, ¹Kyorin University School of Medicine, Tokyo, Japan, ²Kyorin University School of Medicine, Yokohoma, Japan
Background/Purpose: Contrary to Western countries, MPO-ANCA-associated vasculitis (MPO-AAV) is dominant in Japan or Asian countries. It is possible that therapeutic responses to EGPA with mepolizumab…
Abstract Number: 0837 • ACR Convergence 2023
A Randomized, Double-Blind, Sham-Controlled, Clinical Trial of Auricular Vagus Nerve Stimulation for the Treatment of Active Rheumatoid Arthritis
Matthew Baker¹, Sarah Kavanagh², Stanley Cohen³, Alan Matsumoto⁴, Ara Dikranian⁵, John Tesser⁶, Alan Kivitz⁷, Konstantinos Alataris⁸ and Mark Genovese⁹, ¹Stanford University, Menlo Park, CA, ²Kavanagh Statistical Consulting, LLC, Apex, NC, ³Metroplex Clinical Research Center, Dallas, TX, ⁴Arthritis and Rheumatism Associates, Wheaton, MD, ⁵Cabrillo Center for Rheumatic Disease, San Diego, CA, ⁶Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ⁷Altoona Center for Clinical Research, Duncansville, PA, ⁸Nēsos, Menlo Park, CA, ⁹Stanford University, Sunnyvale, CA
Background/Purpose: Vagus nerve stimulation (VNS) has emerged in recent decades as a potential therapy for RA.We have previously shown that auricular VNS produced an average…
Abstract Number: 036 • 2023 Pediatric Rheumatology Symposium
Predictive Factors of Long-lasting Remission Following Anakinra Withdrawal in Patients with Systemic Juvenile Idiopathic Arthritis After Achievement of Clinical Inactive Disease
Germana Nardini¹, Claudia Bracaglia², Denise Pires Marafon¹, Emanuela Sacco³, Arianna De Matteis¹, Ivan Caiello¹, Giusi Prencipe¹, Fabrizio De Benedetti² and Manuela Pardeo², ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Roma, Italy, ²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy, ³Fondazione Casa Sollievo della Sofferenza, Pediatria, San Giovanni Rotondo, Italy
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a rare autoinflammatory disease of unknown etiology. Several uncontrolled studies showed that early treatment with anakinra is associated…
Abstract Number: 1074 • ACR Convergence 2022
Safety and Efficacy of Dupilumab in Patients with Relapsing and/or Refractory Eosinophilic Granulomatosis with Polyangiitis
Berengere Molina¹, Maria Letizia Urban², Roberto Padoan³, Pavel Novikov⁴, Camille Taillé⁵, Marco Caminati⁶, Christine Christides⁷, nicolas schleinitz⁸, Laura Moi⁹, Vincent Cottin¹⁰, bertrand godeau¹¹, Laurence Bouillet¹², Paolo Fraticelli¹³, Ann Knight¹⁴, Jan Walter Schroeder¹⁵, Sylvain Marchand-Adam¹⁶, Helder Gil¹⁷, Elena Gelain¹⁸, Giacomo Emmi² and Benjamin Terrier¹⁹, ¹Department of Internal Medicine, Cochin Hospital, Paris, France, ²Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ³University of Padova, Padova, Italy, ⁴Tareev’s Clinic, Sechenov First Moscow State Medical University, Moscow, Russia, ⁵Pulmonology department, Bichat Hospital, Paris, Ile-de-France, France, ⁶Verona University Hospital, University of Verona, Verona, Italy, ⁷Avignon hospital, Avignon, France, ⁸Aix Marseille university, AP-HM, Marseille, France, ⁹Centre hospitalier universitaire vaudois, Lausanne, Lausanne, Switzerland, ¹⁰Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, ¹¹Department of Internal Medicine, National Referral Center for Adult's Immune Cytopenias, Mondor Hospital, Créteil, France, ¹²Grenoble University Hospital, Grenoble, France, ¹³Department of Internal Medicine, Ospedali Riuniti di Ancona, Ancona, Italy, ¹⁴Akademiska sjukhuset, Uppsala, Sweden, ¹⁵ASST GOM Niguarda, Milano, Italy, ¹⁶Tours University Hospital, Tours, France, ¹⁷Besancon University Hospital, Besançon, France, ¹⁸Meyer Children’s University Hospital of Firenze, Florence, Italy, ¹⁹National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is an ANCA-associated vasculitides characterized by asthma, blood and tissue eosinophilia and systemic manifestations. Glucocorticosteroids (GCs)-dependent asthma and/or disabling…
Abstract Number: 1079 • ACR Convergence 2022
Intravenous Immunoglobulin in Antineutrophil Cytoplasmic Antibody-associated Vasculitis: Study of 28 Cases from a Single Univeristary Hospital
Fabricio Benavides Villanueva¹, Cristina Corrales¹, Vanesa Calvo Río², Javier Loricera³, Nuria Aviles⁴, Juan M Blanco Madrigal⁵, Santos Castañeda⁶, Miguel Angel Gonzalez Gay⁷ and Ricardo Blanco³, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Valdecilla Hospital, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Hospital Universitario Perpetuo Socorro, Albacete, Spain, ⁵Basurto University Hospital, Bilbao, Spain, ⁶Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁷Hospital Universitario Marques de Valdecilla, Lugo, Spain
Background/Purpose: Anti neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) includes granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA) or microscopic polyarteritis (MPA). Standard treatment is…
Abstract Number: 1107 • ACR Convergence 2022
Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): A Prospective Study
Xinlei Ma, Fan Yang, Jin Lin and Weiqian Chen, Division of Rheumatology, the First Affiliated Hospital, Zhejiang University School of Medicine, HangZhou, China
Background/Purpose: Polymyalgia Rheumatica (PMR) is a common inflammatory disease in elderly persons whose pathogenesis is unclear. Glucocorticoids are the first-line drugs for patients with PMR,…
Abstract Number: 1375 • ACR Convergence 2022
Short-term Efficacy of Baricitinib in Children with Refractory And/or Severe Juvenile Dermatomyositis
zhaoling wang¹, meiping lu² and qi zheng¹, ¹Department of Rheumatology Immunology and Allergy, Children's Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China, ²Children’s Hospital of Zhejiang University Medical School, Zhejiang, China
Background/Purpose: To evaluate the short-term efficacy and safety of baricitinib in children withrefractory and/or severe juvenile dermatomyositis (rsJDM) in a real-world setting. Methods: A monocentric…
Abstract Number: 1723 • ACR Convergence 2022
CXCR4-targeted Functionally Selective Immunomodulator Shows Robust Efficacy in Pristane-induced Murine Lupus Model
Annegret Van der Aa¹, Simon Tessier¹, Jean-Philippe Herbeuval² and Joël Crouzet¹, ¹Ermium Therapeutics SAS, Paris, France, ²CBMIT, CNRS UMR 8601, Université Paris Cité, Paris, France
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, heterogeneous autoimmune disease. There is still a high unmet need to improve current treatment options. The chemokine…
Abstract Number: 1890 • ACR Convergence 2022
The Efficacy of Intra-articular Triamcinolone Acetonide 10 mg vs. 40 mg in Patients with Knee Osteoarthritis: a Non-inferiority, Randomized, Controlled, Double-blind, Multicenter Study
Sumapa Chaiamnuay¹, Komchan Utamawatin², Ong-art Phruetthiphat² and Rit Apinyankul³, ¹Phramongkutklao hospital, Nonthaburi, Thailand, ²Phramongkutklao Hospital, Bangkok, Thailand, ³Konkaen University Hospital, Konkaen, Thailand
Background/Purpose: Intra-articular (IA) corticosteroid injection is recommended in refractory knee osteoarthritis patients. However, 40-mg of triamcinolone IA every 3 months for 2 years reduces cartilage…
Abstract Number: 2014 • ACR Convergence 2022
Difficult to Treat Rheumatoid Arthritis: Prevalence of Different Objective Patterns, Predictive Characteristics, and Associated Factors in 1-Year Follow-Up
Einer Sanchez-Prado, ronald Perez, Laura Cuellar, jonatan mareco, Santiago Ruta, Sebastian Magri and Rodrigo Garcia Salinas, Hospital Italiano de La Plata, La Plata, Argentina
Background/Purpose: Difficult-to-Treat Rheumatoid Arthritis (RA) (D2T), is a concept recently defined by EULAR, it refers to patients who do not achieve the therapeutic target, who…
Abstract Number: 0025 • ACR Convergence 2022
Wnt Pathway/Innate Immunity Equilibrium in OA Articular Cells
Eloi Franco-Trepat¹, Ana Alonso Pérez¹, María Guillán-Fresco², Miriam López Fagúndez¹, Andrés Pazos-Pérez³, Antia Crespo Golmar⁴, María Piñeiro-Ramil⁵, Ana Lois Iglesias⁶, Alberto Jorge-Mora¹ and Rodolfo Gomez¹, ¹MSP Group - Institute IDIS - CHUS - SERGAS, Santiago de Compostela, Spain, ²MSP Group - Institute IDIS - CHUS - SERGAS, Catoira, Spain, ³MSP Group - Institute IDIS - CHUS - SERGAS, Pontevedra, Spain, ⁴MSP Group - Institute IDIS - CHUS - SERGAS, León, Spain, ⁵MSP Group - Institute IDIS - CHUAC - SERGA, A Coruña, Spain, ⁶MSP Group - Institute IDIS - CHUAC - SERGAS, A Coruña, Spain
Background/Purpose: The progressive degradation of osteoarthritis (OA) cartilage has been associated with articular innate immune responses (IIR) mediated by the Toll-like receptor 4 (TLR4). Additionally,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].